	US 12,319,734 B2
	Anti-TMEM106B antibodies and methods of use thereof
Arnon Rosenthal, Woodside, CA (US); Eric Brown, South San Francisco, CA (US); Tina Schwabe, San Francisco, CA (US); Angie Yee, San Francisco, CA (US); and Herve Rhinn, San Francisco, CA (US)
Assigned to ALECTOR LLC, South San Francisco, CA (US)
Filed by ALECTOR LLC, South San Francisco, CA (US)
Filed on Aug. 18, 2022, as Appl. No. 17/820,686.
Application 17/820,686 is a division of application No. 16/959,081, granted, now 11,440,957, previously published as PCT/US2018/067236, filed on Dec. 21, 2018.
Claims priority of provisional application 62/612,098, filed on Dec. 29, 2017.
Prior Publication US 2023/0303681 A1, Sep. 28, 2023
Int. Cl. C07K 16/18 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/28 (2013.01) [C07K 2317/34 (2013.01); C07K 2317/56 (2013.01)]

27 Claims

1. An isolated nucleic acid comprising a nucleic acid sequence encoding an antibody that binds to human TMEM106B, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and light chain variable region comprise:

(a) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 4, 37, 80, 122, 162, and 187, respectively;

(b) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 5, 38, 81, 123, 163, and 188, respectively;

(c) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 11, 44, 87, 123, 169, and 188, respectively;

(d) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 12, 45, 88, 129, 170, and 194, respectively;

(e) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 13, 46, 89, 130, 171, and 195, respectively;

(f) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 14, 47, 90, 131, 170, and 196, respectively;

(g) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 15, 48, 91, 132, 172, and 197, respectively;

(h) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 6, 53, 96, 136, 175, and 201, respectively;

(i) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 14, 54, 97, 137, 176, and 202, respectively;

(i) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 19, 55, 98, 138, 169, and 203, respectively;

(k) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 11, 58, 101, 138, 169, and 207, respectively;

(l) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 14, 64, 107, 146, 161, and 202, respectively;

(m) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 25, 67, 110, 149, 161, and 196, respectively;

(n) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 26, 68, 111, 150, 181, and 214, respectively;

(o) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 27, 69, 112, 151, 181, and 215, respectively;

(p) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 29, 71, 111, 153, 181, and 214, respectively;

(g) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 33, 75, 117, 156, 161, and 220, respectively;

(r) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 9, 42, 85, 127, 167, and 192, respectively;

(s) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 7, 40, 83, 125, 165, and 190, respectively;

(t) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 9, 60, 103, 143, 167, and 192, respectively;

(u) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 21, 61, 104, 144, 169, and 209, respectively;

(v) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 16, 50, 93, 134, 172, and 199, respectively; or

(w) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 13, 46, 89, 141, 171, and 206, respectively; or

(x) an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences of SEQ ID NOs: 22, 62, 105, 145, 161, and 210, respectively.